Conference Day One - Wednesday, 4 December
7.30 Check-In & Coffee
8.20 Chair’s Opening Remarks
Plenary Session: Clinical Highlights from 2024
8.30 Making the Leap to Phase 3 Studies: Overcoming Clinical Development & Operational Challenges
9.00From Innovation to Commercialization – CRISPR Medicine Manufacturing Solutions for the Next Decade
9.30 Leveraging EBT-101 Preclinical & Early Clinical Development for New In Vivo Multiplex Editing Programs
10.00 Panel Discussion: Ensuring Diversity, Equity & Inclusivity in Gene Editing Clinical Trials
10.30 Morning Refreshments & Speed Networking
Innovation & Early Development Track
Translating to the Clinic Track
Enabling Precise Small- and Large- Cargo In Vivo Delivery
Moderator: Joseph Nabhan, Vesigen Therapeutics
Advancing Assay Development and Safety
Monitoring Methods
Moderator: Jeffrey Cehelsky, Intellia Therapeutics
11.30 Novel Delivery Platforms for Efficient and Specific In Vivo Delivery of Genome Editing Payloads
Luca Biasco, Vice President,
Translational Sciences, Nvelop Therapeutics
11.30 Leveraging Duplex Sequencing for Highly Sensitive
Off-Target Assessment
Barrett Nuttall, Director, AstraZeneca
12.00 Highly Efficient Integrase Technology for Site-Specific
Genomic Integration of Large DNA Payload
Omid Harandi, Chief Scientific Officer, Komo Biosciences
12.30 Clinical Safety Monitoring Strategies for Gene Editing
Therapies
Priya Chockalingam, Vice President, Head of Clinical
Bioanalytics & Translational Sciences, Beam Therapeutics
13:00 Lunch Briefing Hosted by Edilytics
Innovation & Early Development Track
Translating to the Clinic Track
Optimizing Guide Molecules & Advancing Analytical Platforms
Moderator: Joseph Nabhan, Vesigen Therapeutics
Overcoming Key Regulatory & Translation Challenges
Moderator: Jeffrey Cehelsky, Intellia Therapeutics
1.30 The CRISPR Analytics Platform™: A New Biosensor
Tool Providing Advanced In Vitro CRISPR Analytics To
Maximize Gene Editing and Bioprocessing Outcomes
Jason Lehmann, Senior Product Marketing Manager, CRISPR
QC
1.30 Regulatory Strategies to Enable the Clinical Trial
Applications of Genome Editing Products
Claire Levée, Director, Regulatory Affairs, Genetic Medicine,
Regeneron Pharmaceuticals
2.00 Prime Editing pegRNA: Optimizing Guides
Andrew Anzalone, Director, Head of Prime Editing Platform,
Prime Medicine
2.00 Extended Audience Discussion: Outlining a Path from
Preclinical Models to the Clinic
Vivian Choi, Head of Liver, Metabolic, Lung, Eye & Ear
Disease Unit, Prime Medicine
2.30 Optimizing Guide RNAs for In Vivo Editing
Bryant Chica, Scientist II, Analytical Chemistry & Structural
Biology, Editas Medicine
3.00 Innovation in Guide RNA Manufacturing: Dual
Purification Technique
Amanda Haas, Business Development Manager, Nucleic Acid
Solutions, Agilent Technologies